EVOQ Therapeutics, Inc.

About EVOQ Therapeutics, Inc.

EVOQ Therapeutics is dedicated to developing innovative immunotherapies to improve the lives of individuals with autoimmune diseases. Their mission focuses on targeting the root cause of these diseases to restore the body's native immune tolerance using breakthrough technologies.

Products & Services

NanoDisc Technology:A proprietary platform that delivers disease-specific antigens to dendritic cells in lymph nodes, liver, and spleen, enhancing immune response up to 30 times more effectively than other approaches. Proven in preclinical models for Type 1 Diabetes, Multiple Sclerosis, and Lupus, it offers targeted therapy with simple subcutaneous administration.

Specialties

Immunotherapies for autoimmune diseases NanoDisc technology Targeting immune tolerance Therapies for Type 1 Diabetes, Celiac Disease, Lupus, and Multiple Sclerosis

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2025-10-14 FD: 2025-10-14	1 investors
2	RT: Grant T: - FT: Grant	A: 2000000 MR: - FA: $2 million FAN: 2000000	D: 2024-08-29 FD: 2024-08-29	1 investors

Grant Latest

2025-10-14

$2.0M

1 investor (Pro only)

Grant 2024-08-29

$2.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

D

David Giljohann

Chief Executive Officer

LinkedIn (Pro only)

G

Greg Barrett

Chief Operating Officer

LinkedIn (Pro only)

J

James Moon

Co-Founder and Chief Scientific Officer

LinkedIn (Pro only)

A

Anna Schwendeman

Co-Founder and Vice President of Preclinical Development

W

Weston Daniel, PhD

Chief Development Officer

W

William Brinkerhoff

Co-Founder and Board Chair

View 4 more team members with Pro

Unlock Full Team Directory

Recent News